Consequently, for tumors (HCC) with high levels of oncofetal cells and VEGF expression, the impact of anti-VEGF-A is likely to be more apparent due to their role in oncofetal reprogramming and orchestrating an immunosuppressive TME. This evidence concerns the gene VEGFA and hepatocellular carcinoma.